vs

Side-by-side financial comparison of EPR PROPERTIES (EPR) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $182.9M, roughly 1.1× EPR PROPERTIES). EPR PROPERTIES runs the higher net margin — 36.6% vs -62.0%, a 98.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 3.2%). EPR PROPERTIES produced more free cash flow last quarter ($269.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 4.6%).

EPR Properties, formerly Entertainment Properties Trust, is a real estate investment trust based in Kansas City, Missouri, that invests in amusement parks, movie theaters, ski resorts, and other entertainment properties. It owns 353 properties as of 2022.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

EPR vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.1× larger
RARE
$207.3M
$182.9M
EPR
Growing faster (revenue YoY)
RARE
RARE
+22.7% gap
RARE
25.9%
3.2%
EPR
Higher net margin
EPR
EPR
98.6% more per $
EPR
36.6%
-62.0%
RARE
More free cash flow
EPR
EPR
$370.0M more FCF
EPR
$269.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
4.6%
EPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EPR
EPR
RARE
RARE
Revenue
$182.9M
$207.3M
Net Profit
$66.9M
$-128.6M
Gross Margin
Operating Margin
56.8%
-54.7%
Net Margin
36.6%
-62.0%
Revenue YoY
3.2%
25.9%
Net Profit YoY
897.0%
3.5%
EPS (diluted)
$0.80
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPR
EPR
RARE
RARE
Q4 25
$182.9M
$207.3M
Q3 25
$182.3M
$159.9M
Q2 25
$178.1M
$166.5M
Q1 25
$175.0M
$139.3M
Q4 24
$177.2M
$164.6M
Q3 24
$180.5M
$139.5M
Q2 24
$173.1M
$147.0M
Q1 24
$167.2M
$108.8M
Net Profit
EPR
EPR
RARE
RARE
Q4 25
$66.9M
$-128.6M
Q3 25
$66.6M
$-180.4M
Q2 25
$75.6M
$-115.0M
Q1 25
$65.8M
$-151.1M
Q4 24
$-8.4M
$-133.2M
Q3 24
$46.6M
$-133.5M
Q2 24
$45.1M
$-131.6M
Q1 24
$62.7M
$-170.7M
Operating Margin
EPR
EPR
RARE
RARE
Q4 25
56.8%
-54.7%
Q3 25
53.5%
-106.9%
Q2 25
62.5%
-64.8%
Q1 25
58.1%
-102.6%
Q4 24
25.5%
-74.3%
Q3 24
51.4%
-94.6%
Q2 24
45.9%
-79.1%
Q1 24
58.8%
-151.9%
Net Margin
EPR
EPR
RARE
RARE
Q4 25
36.6%
-62.0%
Q3 25
36.5%
-112.8%
Q2 25
42.5%
-69.0%
Q1 25
37.6%
-108.5%
Q4 24
-4.7%
-80.9%
Q3 24
25.8%
-95.7%
Q2 24
26.1%
-89.5%
Q1 24
37.5%
-156.8%
EPS (diluted)
EPR
EPR
RARE
RARE
Q4 25
$0.80
$-1.28
Q3 25
$0.79
$-1.81
Q2 25
$0.91
$-1.17
Q1 25
$0.78
$-1.57
Q4 24
$-0.19
$-1.34
Q3 24
$0.53
$-1.40
Q2 24
$0.51
$-1.52
Q1 24
$0.75
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPR
EPR
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$90.6M
$421.0M
Total DebtLower is stronger
$2.9B
Stockholders' EquityBook value
$2.3B
$-80.0M
Total Assets
$5.7B
$1.5B
Debt / EquityLower = less leverage
1.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPR
EPR
RARE
RARE
Q4 25
$90.6M
$421.0M
Q3 25
$13.7M
$202.5M
Q2 25
$13.0M
$176.3M
Q1 25
$20.6M
$127.1M
Q4 24
$22.1M
$174.0M
Q3 24
$35.3M
$150.6M
Q2 24
$33.7M
$480.7M
Q1 24
$59.5M
$112.3M
Total Debt
EPR
EPR
RARE
RARE
Q4 25
$2.9B
Q3 25
$2.8B
Q2 25
$2.8B
Q1 25
$2.8B
Q4 24
$2.9B
Q3 24
$2.9B
Q2 24
$2.8B
Q1 24
$2.8B
Stockholders' Equity
EPR
EPR
RARE
RARE
Q4 25
$2.3B
$-80.0M
Q3 25
$2.3B
$9.2M
Q2 25
$2.3B
$151.3M
Q1 25
$2.3B
$144.2M
Q4 24
$2.3B
$255.0M
Q3 24
$2.4B
$346.8M
Q2 24
$2.4B
$432.4M
Q1 24
$2.4B
$140.3M
Total Assets
EPR
EPR
RARE
RARE
Q4 25
$5.7B
$1.5B
Q3 25
$5.5B
$1.2B
Q2 25
$5.6B
$1.3B
Q1 25
$5.5B
$1.3B
Q4 24
$5.6B
$1.5B
Q3 24
$5.7B
$1.5B
Q2 24
$5.6B
$1.6B
Q1 24
$5.7B
$1.3B
Debt / Equity
EPR
EPR
RARE
RARE
Q4 25
1.26×
Q3 25
1.19×
Q2 25
1.20×
Q1 25
1.20×
Q4 24
1.23×
Q3 24
1.19×
Q2 24
1.16×
Q1 24
1.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPR
EPR
RARE
RARE
Operating Cash FlowLast quarter
$421.0M
$-99.8M
Free Cash FlowOCF − Capex
$269.2M
$-100.8M
FCF MarginFCF / Revenue
147.1%
-48.6%
Capex IntensityCapex / Revenue
82.9%
0.5%
Cash ConversionOCF / Net Profit
6.29×
TTM Free Cash FlowTrailing 4 quarters
$568.5M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPR
EPR
RARE
RARE
Q4 25
$421.0M
$-99.8M
Q3 25
$136.5M
$-91.4M
Q2 25
$87.3M
$-108.3M
Q1 25
$99.4M
$-166.5M
Q4 24
$393.1M
$-79.3M
Q3 24
$122.0M
$-67.0M
Q2 24
$78.7M
$-77.0M
Q1 24
$99.5M
$-190.7M
Free Cash Flow
EPR
EPR
RARE
RARE
Q4 25
$269.2M
$-100.8M
Q3 25
$132.1M
$-92.7M
Q2 25
$82.4M
$-110.7M
Q1 25
$84.7M
$-167.8M
Q4 24
$129.2M
$-79.5M
Q3 24
$121.5M
$-68.6M
Q2 24
$71.3M
$-79.0M
Q1 24
$65.0M
$-193.9M
FCF Margin
EPR
EPR
RARE
RARE
Q4 25
147.1%
-48.6%
Q3 25
72.5%
-58.0%
Q2 25
46.3%
-66.5%
Q1 25
48.4%
-120.5%
Q4 24
72.9%
-48.3%
Q3 24
67.3%
-49.2%
Q2 24
41.2%
-53.7%
Q1 24
38.9%
-178.2%
Capex Intensity
EPR
EPR
RARE
RARE
Q4 25
82.9%
0.5%
Q3 25
2.4%
0.8%
Q2 25
2.7%
1.5%
Q1 25
8.4%
1.0%
Q4 24
148.9%
0.1%
Q3 24
0.3%
1.2%
Q2 24
4.2%
1.4%
Q1 24
20.6%
3.0%
Cash Conversion
EPR
EPR
RARE
RARE
Q4 25
6.29×
Q3 25
2.05×
Q2 25
1.15×
Q1 25
1.51×
Q4 24
Q3 24
2.62×
Q2 24
1.74×
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPR
EPR

Experiential Reportable Operating Segment$173.3M95%
Education Reportable Operating Segment$9.5M5%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons